Literature DB >> 9619835

PTEN mutations in gliomas and glioneuronal tumors.

E M Duerr1, B Rollbrocker, Y Hayashi, N Peters, B Meyer-Puttlitz, D N Louis, J Schramm, O D Wiestler, R Parsons, C Eng, A von Deimling.   

Abstract

Cytogenetic and loss of heterozygosity studies have suggested the presence of at least one tumor suppressor gene on chromosome 10 involved in the formation of high grade gliomas. Recently, the PTEN gene, also termed MMAC1 or TEP1, on chromosomal band 10q23 has been identified. Initial studies revealed mutations of PTEN in limited series of glioma cell lines and glioblastomas. In order to systematically evaluate the involvement of PTEN in gliomas, we have analysed the entire PTEN coding sequence by SSCP and direct sequencing in a series of 331 gliomas and glioneuronal tumors. PTEN mutations were detected in 20/142 glioblastomas, 1/7 giant cell glioblastomas, 1/2 gliosarcomas, 1/30 pilocytic astrocytomas and 2/22 oligodendrogliomas. No PTEN mutations were detected in 52 astrocytomas, 37 oligoastrocytomas, three subependymal giant cell astrocytomas, four pleomorphic xanthoastrocytomas, 15 ependymomas, 16 gangliogliomas and one dysembryoplastic neuroepithelial tumor. In addition, all tumors were examined for the presence of homozygous deletions of the PTEN gene; these were detected in 7 glioblastomas that did not have PTEN mutations. Therefore, PTEN mutations occur in approximately 20% of glioblastomas but are rare in lower grade gliomas. These findings confirm that PTEN is one of the chromosome 10 tumor suppressor genes involved in the development of glioblastomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9619835     DOI: 10.1038/sj.onc.1201756

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  88 in total

1.  Akt-mediated survival of oligodendrocytes induced by neuregulins.

Authors:  A I Flores; B S Mallon; T Matsui; W Ogawa; A Rosenzweig; T Okamoto; W B Macklin
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  Identification of uncommon chromosomal aberrations in the neuroglioma cell line H4 by spectral karyotyping.

Authors:  D Krex; B Mohr; M Hauses; G Ehninger; H K Schackert; G Schackert
Journal:  J Neurooncol       Date:  2001-04       Impact factor: 4.130

Review 3.  Pulling strings below the surface: hormone receptor signaling through inhibition of protein tyrosine phosphatases.

Authors:  X Espanel; S Wälchli; R P Gobert; M El Alama; M L Curchod; N Gullu-Isler; R Hooft van Huijsduijnen
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

Review 4.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

5.  The PEA-15 protein regulates autophagy via activation of JNK.

Authors:  Barbara C Böck; Katrin E Tagscherer; Anne Fassl; Anika Krämer; Ina Oehme; Hans-Walter Zentgraf; Martina Keith; Wilfried Roth
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

6.  A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.

Authors:  Warren P Mason; Mary Macneil; Petr Kavan; Jacob Easaw; David Macdonald; Brian Thiessen; Shweta Urva; Zarnie Lwin; Lynn McIntosh; Elizabeth Eisenhauer
Journal:  Invest New Drugs       Date:  2011-12-09       Impact factor: 3.850

7.  Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells.

Authors:  A Perren; P Komminoth; P Saremaslani; C Matter; S Feurer; J A Lees; P U Heitz; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

8.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

Authors:  X P Zhou; O Gimm; H Hampel; T Niemann; M J Walker; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

9.  A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression.

Authors:  Warren P Mason; Karl Belanger; Garth Nicholas; Isabelle Vallières; David Mathieu; Petr Kavan; Annick Desjardins; Antonio Omuro; Didier Reymond
Journal:  J Neurooncol       Date:  2011-11-03       Impact factor: 4.130

10.  [Exploration of tumor suppressors p16INK4a and p14ARF in oral leukoplakias].

Authors:  Matthias Nitsche; Susanne Koy; Michael Mörz; Rainer Koch; Uwe Eckelt
Journal:  Mund Kiefer Gesichtschir       Date:  2007-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.